Medical News
13 articles on Medical News, written by Shotlee and medically reviewed for clinical accuracy.
Svemia Approved: What Canada's New Semaglutide Generic Means for You
Canada's Health Department has cleared Apotex's Svemia, marking a major milestone for generic semaglutide availability and weight loss treatment access.
7 min read
Ozempic Alternative Found: Stanford’s BRP Peptide Breakthrough
A new study reveals BRP, a natural peptide, may offer the benefits of Ozempic without common side effects.
7 min read
Oral Wegovy's Record-Breaking Launch: The New Era of Needle-Free Weight Loss
Novo Nordisk's Wegovy oral formulation has achieved unprecedented prescription rates, marking a pivotal shift in obesity care and intensifying competition with Eli Lilly.
8 min read
Retatrutide Phase 3 Results: 28% Weight Loss and the Triple Agonist Promise
Eli Lilly has released pivotal Phase 3 trial data for retatrutide, a triple agonist showing up to 28% body weight reduction and significant improvements in diabetes and sleep apnea.
7 min read
Beyond Ozempic: New Muscle-Burning Pill Reshaping Diabetes Care
A new experimental medication from Karolinska Institute targets muscle metabolism rather than appetite, offering a potential alternative to Ozempic and Wegovy with fewer side effects.
6 min read
GLP-1s & Eating Disorders: A Growing Concern for Patients and Doctors
The effectiveness of GLP-1 medications like Ozempic, Wegovy, and Mounjaro for weight loss has led to widespread adoption. However, a concerning trend is emerging: individuals with a history of or current eating disorders are increasingly turning to these drugs, raising alarm bells among healthcare professionals dedicated to eating disorder recovery.
9 min read
Retatrutide Breakthrough: Can This Molecule Rival Gastric Bypass Surgery?
New data suggests Eli Lilly's retatrutide could deliver up to 28% weight loss, potentially rivaling bariatric surgery. Learn about efficacy and safety.
8 min read
FDA Considers Compounding Access for Unproven Peptides: What Patients Need to Know
The FDA is evaluating the regulation of specific peptides amid growing demand. We break down the science, the risks, and the clinical implications.
2 min read
GLP-1 and SGLT2 Combo Cuts Mortality 29% in T2D Study
A large German study reveals that pairing GLP-1 receptor agonists with SGLT2 inhibitors significantly lowers all-cause mortality and cardiovascular risks in type 2 diabetes patients compared to SGLT2 inhibitors alone. Common combinations like dulaglutide plus empagliflozin showed a 29% mortality reduction. Experts highlight synergy but urge caution on potential harms.
5 min read
Research: 4p Hot Drink Mimics GLP-1 for Weight Loss
A scientific review shows certain affordable foods and drinks, including a 4p cup of green tea, could mimic GLP-1 inhibitors used in weight loss drugs. These natural compounds may support appetite regulation and blood sugar control. However, experts caution they are not direct alternatives to medications like Ozempic.
2 min read
Wegovy Pill in NJ Stores: Where to Get It
The first oral GLP-1 for weight loss, Wegovy pill, is now available in New Jersey stores. One in eight adults have tried GLP-1 meds, with 20% interested per KFF data. Discover where to buy, costs, and safety info.
2 min read
Wegovy Pill in New Jersey Stores: Where to Obtain It
The new Wegovy GLP-1 pill for weight loss is now accessible in New Jersey stores. With growing interest in these medications, this guide covers availability, pricing, and key safety information. Health tracking apps like Shotlee can assist in monitoring progress during use.
2 min read
For Pregnancy, Halting GLP-1s Presents Complex Issues
Research indicates that discontinuing GLP-1 medications around conception or in early pregnancy might carry risks. The study links stopping these drugs to increased gestational weight gain and adverse pregnancy outcomes. Experts emphasize the need for further investigation to fully understand the implications.
3 min read